These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16848770)

  • 1. Minimal residual disease directed therapy for childhood acute myeloid leukaemia: the time is now.
    Goulden N; Virgo P; Grimwade D
    Br J Haematol; 2006 Aug; 134(3):273-82. PubMed ID: 16848770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of childhood acute myeloid leukemia.
    ter Bals E; Kaspers GJ
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):917-29. PubMed ID: 16221060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
    Sutton R; Venn NC; Tolisano J; Bahar AY; Giles JE; Ashton LJ; Teague L; Rigutto G; Waters K; Marshall GM; Haber M; Norris MD;
    Br J Haematol; 2009 Aug; 146(3):292-9. PubMed ID: 19500099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
    Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
    J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal residual disease as a surrogate marker for risk assignment to ALL patients.
    Cazzaniga G; Gaipa G; Rossi V; Biondi A
    Rev Clin Exp Hematol; 2003 Sep; 7(3):292-323. PubMed ID: 15024971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
    J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of BFM trials for childhood ALL.
    Schrappe M
    Ann Hematol; 2004; 83 Suppl 1():S121-3. PubMed ID: 15124702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
    J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of MRD in children undergoing allogeneic stem cell transplantation for ALL.
    Goulden N; Steward C
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):59-70. PubMed ID: 11987916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood.
    Mussolin L; Pillon M; Conter V; Piglione M; Lo Nigro L; Pierani P; Micalizzi C; Buffardi S; Basso G; Zanesco L; Rosolen A
    J Clin Oncol; 2007 Nov; 25(33):5254-61. PubMed ID: 18024872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia].
    Jiang H; Gu LJ; Xue HL; Tang JY; Chen J; Pan C; Chen J; Xu C; Dong L; Zhou M
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):290-4. PubMed ID: 18554450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk-adapted stratification and treatment of childhood acute lymphoblastic leukaemia.
    Schrappe M
    Radiat Prot Dosimetry; 2008; 132(2):130-3. PubMed ID: 19017727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?
    Nabhan C; Coutré S; Hillmen P
    Br J Haematol; 2007 Feb; 136(3):379-92. PubMed ID: 17129223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.
    Maurillo L; Buccisano F; Del Principe MI; Del Poeta G; Spagnoli A; Panetta P; Ammatuna E; Neri B; Ottaviani L; Sarlo C; Venditti D; Quaresima M; Cerretti R; Rizzo M; de Fabritiis P; Lo Coco F; Arcese W; Amadori S; Venditti A
    J Clin Oncol; 2008 Oct; 26(30):4944-51. PubMed ID: 18606980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
    Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches.
    Ryan J; Quinn F; Meunier A; Boublikova L; Crampe M; Tewari P; O'Marcaigh A; Stallings R; Neat M; O'Meara A; Breatnach F; McCann S; Browne P; Smith O; Lawler M
    Br J Haematol; 2009 Jan; 144(1):107-15. PubMed ID: 19016726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk/MRD adapted GMALL trials in adult ALL.
    Gökbuget N; Raff R; Brügge-Mann M; Flohr T; Scheuring U; Pfeifer H; Bartram CR; Kneba M; Hoelzer D
    Ann Hematol; 2004; 83 Suppl 1():S129-31. PubMed ID: 15124705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Copy number alterations in childhood acute lymphoblastic leukemia and their association with minimal residual disease.
    Steinemann D; Cario G; Stanulla M; Karawajew L; Tauscher M; Weigmann A; Göhring G; Ludwig WD; Harbott J; Radlwimmer B; Bartram C; Lichter P; Schrappe M; Schlegelberger B
    Genes Chromosomes Cancer; 2008 Jun; 47(6):471-80. PubMed ID: 18311775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adult acute lymphoblastic leukaemia.
    Bassan R; Gatta G; Tondini C; Willemze R
    Crit Rev Oncol Hematol; 2004 Jun; 50(3):223-61. PubMed ID: 15182827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia.
    Meshinchi S; Arceci RJ
    Oncologist; 2007 Mar; 12(3):341-55. PubMed ID: 17405900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.